Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Acq. announced
|
|
ZEVRA THERAPEUTICS, INC. (KMPH)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 06/18/2020 |
8-K/A
| Regulation FD Disclosure, Financial Statements and Exhibits|
Docs:
|
"KemPharm Issues Letter to Shareholders Celebration, FL – June 18, 2020 – KemPharm, Inc. , a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced that Travis C. Mickle, Ph.D., President and CEO of KemPharm, has issued a Letter to Shareholders in connection with the Company’s 2020 Annual Meeting of Stockholders to be held on June 19, 2020. The letter provides an update on recent events and outlook for the remainder of 2020 and early 2021. The full text of the letter follows below. A MESSAGE FROM OUR CHAIRMAN AND CHIEF EXECUTIVE OFFICER Dear Fellow Shareholders: The last twelve months have been a period of significant advancement for KemPharm. While challenges certainly remain, there are also significant reasons for optimism. Just ..." |
|
| 05/23/2017 |
8-K/A
| Form 8-K/A - Current report [Amend] |
|
|